Achieve Life Sciences Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Achieve Life Sciences wird ein Gewinn- und Umsatzwachstum von 59.2% bzw. 66.5% pro Jahr prognostiziert, während der Gewinn pro Aktie um 61% pro Jahr wachsen soll.

Wichtige Informationen

53.9%

Wachstumsrate der Gewinne

56.5%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.8%
Wachstumsrate der Einnahmen	65.5%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Good
Zuletzt aktualisiert	03 Oct 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Achieve Life Sciences begins phase 2 trial testing cytisinicline for nicotine e-cigarette cessation

Jun 29

Achieve Life Sciences: Initiating Buy, Potential Multi-Billion-Dollar Smoking Cessation Drug

Apr 04

Is Achieve Life Sciences (NASDAQ:ACHV) Weighed On By Its Debt Load?

Mar 22

Is Achieve Life Sciences (NASDAQ:ACHV) In A Good Position To Deliver On Growth Plans?

Sep 27

We Think Achieve Life Sciences (NASDAQ:ACHV) Needs To Drive Business Growth Carefully

Jun 14

We're Keeping An Eye On Achieve Life Sciences' (NASDAQ:ACHV) Cash Burn Rate

Mar 01

Achieve Life Sciences prices stock offering at $7; shares down 2%

Dec 03

Achieve Life Sciences launches equity offering

Nov 30

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:ACHV - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	32	-28	-43	-42	6
12/31/2025	N/A	-42	-47	-45	8
12/31/2024	N/A	-35	-24	-28	8
6/30/2024	N/A	-28	-20	-20	N/A
3/31/2024	N/A	-27	-21	-21	N/A
12/31/2023	N/A	-30	-24	-24	N/A
9/30/2023	N/A	-36	-31	-31	N/A
6/30/2023	N/A	-42	-37	-37	N/A
3/31/2023	N/A	-44	-39	-39	N/A
12/31/2022	N/A	-42	-38	-38	N/A
9/30/2022	N/A	-38	-32	-32	N/A
6/30/2022	N/A	-32	-29	-29	N/A
3/31/2022	N/A	-33	-30	-30	N/A
12/31/2021	N/A	-33	-29	-29	N/A
9/30/2021	N/A	-31	-27	-27	N/A
6/30/2021	N/A	-28	-22	-22	N/A
3/31/2021	N/A	-19	-15	-15	N/A
12/31/2020	N/A	-15	-13	-13	N/A
9/30/2020	N/A	-13	-14	-14	N/A
6/30/2020	N/A	-13	-13	-13	N/A
3/31/2020	N/A	-14	-15	-15	N/A
12/31/2019	N/A	-16	-15	-15	N/A
9/30/2019	N/A	-17	-15	-15	N/A
6/30/2019	N/A	-16	-15	-15	N/A
3/31/2019	N/A	-16	-13	-13	N/A
12/31/2018	N/A	-13	-11	-11	N/A
9/30/2018	N/A	-13	-11	-11	N/A
6/30/2018	N/A	-16	-13	-13	N/A
3/31/2018	N/A	-13	N/A	-11	N/A
12/31/2017	N/A	-11	N/A	-9	N/A
9/30/2017	N/A	-7	N/A	-6	N/A
3/31/2017	N/A	-1	N/A	0	N/A
12/31/2016	N/A	-1	N/A	0	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ACHV wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: ACHV wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: ACHV wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: ACHV wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Hohe Wachstumseinnahmen: ACHV wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von ACHV in 3 Jahren voraussichtlich hoch sein wird

Achieve Life Sciences Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased by 17% to US$19.71

Price target decreased by 12% to US$24.71

Price target decreased by 8.1% to US$27.57

Forecast to breakeven in 2025

Price target increased by 10% to US$27.43

Price target increased by 14% to US$28.33

Recent updates

Achieve Life Sciences, Inc. Announces Appointment of Mark L. Rubinstein as Head of Medical Affairs

Achieve Life Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

New minor risk - Profitability

Achieve Life Sciences, Inc. Announces CEO Changes

New minor risk - Profitability

Achieve Life Sciences Announces FDA Grants Breakthrough Therapy Designation to Cytisinicline for the Treatment of E-Cigarette or Vaping Nicotine Dependence

Achieve Life Sciences, Inc. to Report Q2, 2024 Results on Aug 13, 2024

Achieve Life Sciences: 1st Half 2025 NDA Filing On Track With FDA Agreement

Achieve Life Sciences, Inc. Announces Initiation of ORCA-OL Clinical Trial Evaluating Long-Term Exposure of Cytisinicline in People who Smoke or Use Nicotine E-Cigarettes

New minor risk - Profitability

Achieve Life Sciences, Inc. Announces Publication of Cytisinicline Vaping Cessation Trial Results in JAMA Internal Medicine

Achieve Life Sciences, Inc., Annual General Meeting, Jun 05, 2024

Achieve Life Sciences, Inc. to Report Q1, 2024 Results on May 09, 2024

Price target decreased by 17% to US$19.71

Achieve Life Sciences, Inc. Announces Data from Cytisinicline ORCA Program to Be Presented at the 2024 Society for Research on Nicotine and Tobacco Annual Meeting

Achieve Life Sciences, Inc. to Report Q4, 2023 Results on Mar 28, 2024

New major risk - Financial position

Achieve Life Sciences, Inc. has filed a Follow-on Equity Offering in the amount of $60.000002 million.

Does Achieve Life Sciences (NASDAQ:ACHV) Have A Healthy Balance Sheet?

New minor risk - Profitability

Price target decreased by 12% to US$24.71

New minor risk - Share price stability

Price target decreased by 8.1% to US$27.57

Achieve Life Sciences, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Is Achieve Life Sciences (NASDAQ:ACHV) Using Debt In A Risky Way?

Achieve Life Sciences, Inc. Announces Presentation of Cytisinicline E-Cigarette Cessation (ORCA-V1) Results at Society for Research on Nicotine and Tobacco Europe (SRNT-E) Annual Meeting

New minor risk - Market cap size

New major risk - Financial position

Achieve Life Sciences, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Achieve Life Sciences, Inc. Announces Publication of Cytisinicline Phase 3 ORCA-2 Smoking Cessation Trial in Journal of the American Medical Association (JAMA)

Achieve Life Sciences, Inc. Reports Statistically Significant Smoking Cessation Benefit for Cytisinicline in Second, Confirmatory Phase 3 Clinical Trial

Forecast to breakeven in 2025

Price target increased by 10% to US$27.43

Executive Chairman exercised options and sold US$69k worth of stock

High number of new directors

Is Achieve Life Sciences (NASDAQ:ACHV) A Risky Investment?

Price target increased by 14% to US$28.33

Achieve Life Sciences, Inc. Announces Last Subject Dosed in Phase 2 Orca-V1 Trial of Cytisinicline for E-Cigarette Cessation

Dialectic Capital Engages in Discussions with Achieve Life Sciences

Achieve Life Sciences, Inc. Announces That the Final Subject of the Company’s Phase 3 ORCA-3 Trial Has Completed Treatment in the Study

Achieve Life Sciences, Inc. Receives Written Notification from the Listing Qualifications Staff of the Nasdaq Stock Market

Consensus revenue estimates fall by 33%

Price target decreased to US$28.13

Achieve Life Sciences, Inc. announced that it expects to receive CAD 18.930777 million in funding

Achieve Life Sciences, Inc. Announces Early Completion of Target Enrollment in Cytisinicline E-Cigarette Cessation Trial

Achieve Life Sciences, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Achieve Announces Completion of Target Enrollment in the Phase 3 ORCA-3 Trial of Cytisinicline for Smoking Cessation

Consensus revenue estimates fall by 33%

Achieve Life Sciences, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Achieve Life Sciences Announces Initiation of Phase 2 ORCA-V1 Clinical Trial Evaluating Cytisinicline for Nicotine E-Cigarette Cessation

Achieve Life Sciences begins phase 2 trial testing cytisinicline for nicotine e-cigarette cessation

Achieve Life Sciences Inc. Awarded Grant from the National Institutes of Health to Conduct Phase 2 Trial of Cytisinicline in Nicotine E-Cigarette Users

Price target increased to US$34.13

Achieve Life Sciences Announces Positive Topline Results from Phase 3 ORCA-2 Clinical Trial of Cytisinicline in Adult Smokers

Price target decreased to US$31.50

Achieve Life Sciences, Inc. to Report Q1, 2022 Results on May 12, 2022

Achieve Life Sciences, Inc., Annual General Meeting, May 31, 2022

Achieve Life Sciences: Initiating Buy, Potential Multi-Billion-Dollar Smoking Cessation Drug

Is Achieve Life Sciences (NASDAQ:ACHV) Weighed On By Its Debt Load?

Consensus revenue estimates fall by 73%

Achieve Life Sciences, Inc. to Report Q4, 2021 Results on Mar 10, 2022

Achieve Life Sciences Announces Initiation of the Phase 3 Orca-3 Clinical Trial Evaluating Cytisinicline for Smoking Cessation

Achieve Life Sciences, Inc. Announces Completion of Last Subject, Last Follow-Up Visit in Phase 3 ORCA-2 Trial of Cytisinicline for Smoking Cessation

Achieve Life Sciences Announces Phase 3 ORCA-2 Trial of Cytisinicline in Smoking Cessation Clears Final Review by Data Safety Monitoring Committee (DSMC)

Is Achieve Life Sciences (NASDAQ:ACHV) In A Good Position To Deliver On Growth Plans?

Price target decreased to US$39.50

Price target decreased to US$41.50

We Think Achieve Life Sciences (NASDAQ:ACHV) Needs To Drive Business Growth Carefully

Achieve Life Sciences, Inc. has completed a Follow-on Equity Offering in the amount of $20.000001 million.